Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19

Thumbnail
View/Open
Issue date
2021
Author
Buxeda, Anna
Arias Cabrales, Carlos
Pérez Sáez, María José
Cacho, Judit
Cabello Pelegrin, Sheila
Melilli, Edoardo
Aladrén, María José
Galeano, Cristina
Lorenzo, Inmaculada
Mazuecos, Auxiliadora
Saura, Isabel María
Franco, Antonio
Ruiz Fuentes, María del Carmen
Sánchez Cámara, Luis Alberto
Siverio, Orlando
Martín Conde, María Luisa
González García, Elena
López, Verónica
Martin Moreno, Paloma Leticia
Moina, Iñigo
Moral Berrio, Esperanza
Moreso, Francesc
Portolés, José María
Santana Estupiñán, Raquel
Zárraga, Sofía
Canal, Cristina
Sánchez Álvarez, Emilio
Pascual, Julio
Crespo, Marta
Suggested citation
Buxeda, Anna; Arias Cabrales, Carlos; Pérez Sáez, María José; Cacho, Judit; Cabello Pelegrin, Sheila; Melilli, Edoardo; ... Crespo, Marta. (2021) . Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19. Kidney International Reports, 2021, vol. 6, núm. 9, p. 2305-2315. https://doi.org/10.1016/j.ekir.2021.06.023.
Impact

Google Scholar logo  Google Scholar
Share
Export to Mendeley
Metadata
Show full item record
Abstract
Introduction:Remdesivir has demonstrated antiviral activity against coronavirus, shortening the time torecovery in adults hospitalized with moderate/severe COVID-19. Severe adverse events such as acutekidney injury have been reported. Scant data are available on the use and safety of remdesivir in kidneytransplant recipients.Methods:We present a multicenter cohort study of 51 kidney transplant recipients with COVID-19 treatedwith remdesivir. Outcomes and safety were assessed.Results:Mean age at diagnosis was 60 years, with a median time since kidney transplant of 4.5years. Mean time since admission to remdesivir was 2 days. Twenty-eight patients (54.9%) requiredmechanical ventilation (19 noninvasive). Mortality was 18.9% and markedly higher if aged$65 years(45% vs. 3.2% in younger patients). Acute kidneyinjury was present in 27.7% of patients, but wasdiagnosed in 50% before treatment. No patients required remdesivir discontinuation because ofadverse events. We did notfind significant hepatoxicity or systemicsymptoms resulting from thedrug. Conclusion:In our cohort of kidney transplant recipients, remdesivir was well tolerated and safe in renaland hepatic toxicity, but randomized trials are needed to assess its efficacy.
URI
http://hdl.handle.net/10459.1/72336
DOI
https://doi.org/10.1016/j.ekir.2021.06.023
Is part of
Kidney International Reports, 2021, vol. 6, núm. 9, p. 2305-2315
Collections

The following license files are associated with this item:

cc-by-nc-nd (c) International Society of Nephrology, 2021
Except where otherwise noted, this item's license is described as cc-by-nc-nd (c) International Society of Nephrology, 2021